BioSpace News Archive

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the company has dosed the first patient in its phase II clinical trial of pyrilutamide in China for the treatment of androgenetic alopecia female patients.

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today presented new preclinical data from its STAT3 degrader program at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, reported its third quarter and year to date September 30, 2021 operating and financial results.

Vaccitech plc announced its financial results for the third quarter, ended September 30, 2021, and provided an overview of the Company’s recent corporate developments.

Checkmate Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, announced third quarter 2021 financial results and provided a business update.

Akouos, Inc., a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, reports financial results for the third quarter ended September 30, 2021, and provides business highlights.

Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the presentation of new preclinical data supporting its Glypican-3 (GPC3) targeted allogeneic, off-the-shelf gamma delta chimeric antigen receptor (CAR) T cell development candidate for solid tumors at the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting.